 SAN JOSE, Calif., Aug. 13, 2021 GLOBE NEWSWIRE -- Rani Therapeutics Holdings, Inc. Nasdaq:RANI Rani Therapeutics or Rani, a clinical stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics today announced the final closing of its initial public offering of 7,666,667 shares of its Class A common stock, which includes 1,000,000 shares sold pursuant to the full exercise by the underwriters of their option to purchase additional shares, at a public offering price of 11.00 per share. The offering of 6,666,667 shares closed on August 3, 2021. The closing of the underwriters partial exercise of 500,000 shares occurred on August 11, 2021, and the closing of the underwriters exercise of their remaining option of 500,000 shares occurred on August 13, 2021. The gross proceeds to Rani from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately 84.3 million. All of the shares in the offering were sold by Rani. 